Free heel prick incisor trial

Specialist maternity products supplier, Central Medical Supplies (CMS), is offering hospital Trusts a free trial of the Gentleheel heel prick incisor.

Used for infant blood spot sampling, Gentleheel features a tri-bevel blade, which is said to give a smoother, sharper and less traumatic incision. The cutting action of Gentleheel is designed to provide a more consistent incision and features include: multiple visual indicators to reinforce the incision site; permanent blade retraction to minimise possible injury or re-use; and a hardened stainless steel blade to improve accuracy of the incision depth. Designed to provide improved handling, its welded plastic case prevents accidental exposure to the blade. The four different sizes – MicroPreemie, Preemie, Newborn and Toddler – are colour coded for easy selection. 

Tracey Pavier-Grant, medical sales director at Central Medical Supplies, said: “Gentleheel, which is an arch-shaped incision device, allows healthcare professionals to take sufficient blood samples first time. This causes less distress to the infant and saves a hospital trust time and money.  For a limited time, we’re offering hospital Trusts a free trial of Gentleheel so healthcare professionals can try out the product on infants in their care.” 

To discuss a free trial, contact Tracey Pavier-Grant on 01538 392 596 or email [email protected]

 

 

More about Central Medical Supplies

 

Other news

Upcoming Events

AfPP Residential 2019

York University
8th to the 11th August

Infection Prevention 2019

ACC, Liverpool
22nd - 24th September

Latest Issue

Clinical Services Journal

Clinical Services Journal

Jun 2019

VH202 sterilisation: The need for consistency

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.

CSJ Supplements

CSJ Supplements

Apr 2019

Putting patients and hospitals first

Register now to apply for regular copies of CSJ Supplements and free access to premium content, as well as our regular newsletters.